Three bacterium-plasmid golden combinations facilitate the spread of ST11/CG258 carbapenemase-producing *Klebsiella pneumoniae* in China

Cuidan Li^{1#}, Xiaoyuan Jiang^{1,2#}, Tingting Yang^{1#}, Yingjiao Ju^{1,3#}, Zhe Yin², Liya Yue¹, Guan Ma¹, Xuebing Wang¹, Ying Jing², Xinhua Luo², Shuangshuang Li^{1,3}, Xue Yang^{1,3}, Fei Chen^{1,3,4,5*}, Dongsheng Zhou^{2*}

¹CAS Key Laboratory of Genome Sciences & Information, Beijing Institute of Genomics, Chinese Academy of Sciences, China National Center for Bioinformation, Beijing, China;

²State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China;

³University of Chinese Academy of Sciences, Beijing, China

⁴State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang, China

⁵Beijing Key Laboratory of Genome and Precision Medicine Technologies, Beijing, China

[#]These authors contributed equally to this work.

*To whom correspondence should be addressed. Tel: +86 010 66948503; E-mail: dongshengzhou1977@gmail.com

*Correspondence may also be addressed to Prof. Fei Chen. Tel: +86 010 84097460; Fax: +86 010 84097720; E-mail: chenfei@big.ac.cn

Abstract

Carbapenemase-producing *Klebsiella pneumoniae* (cpKP) poses serious threats to public health. Previous studies showed that only ST11/CG258-cpKP successfully disseminated in China, however, the underlying genetic bases are still unknown. We conducted a comprehensive genomic-epidemiology analysis on 420 cpKP isolates from 70 hospitals in 24 Chinese provinces during 2009-2017 based on short-/long-reads sequencing. Three ‘golden’ combinations of host—*bla*_{KPC}-carrying plasmids (Clade 3.1+3.2—IncFII_{PHN7A8}, Clade 3.1+3.2—IncFII_{PHN7A8}:IncR, Clade 3.3—IncFII_{PHN7A8}:Inc_{pA1763-KPC}) endowed cpKP with advantages both in genotypes (strong-correlation/co-evolution) and phenotypes (resistance/growth/competition), thereby facilitating nationwide spread of ST11/CG258-cpKP. Intriguingly, Bayesian skyline illustrated that the three ‘golden’ combinations might directly lead to the strong population expansion during 2007-2008 and subsequent maintenance of the dissemination of ST11/CG258-cpKP after 2008. We tested drug-resistance profiles and proposed combination treatment regimens for CG258/non-CG258 cpKP. Our findings systematically revealed the molecular-epidemiology and genetic-basis for dissemination of Chinese ST11/CG258 cpKP and reminded us to monitor the ‘golden’ combinations of cpKP-plasmid closely.

Keywords: *Klebsiella pneumoniae*; drug resistance; carbapenemase; plasmid; genomic epidemiology

Introduction

Antimicrobial-resistant *Klebsiella pneumoniae* (KP) is listed as the ‘K’ in ESKAPE pathogens, the six most significant and dangerous causes for antimicrobial-resistant nosocomial infections, and has been recognized as a major threat to global public health (1). Carbapenems (e.g. imipenem and meropenem) are the first choice for treatment of severe or refractory infections caused by KP, but clinical carbapenem-resistant KP isolates spread worldwide in recent years (2). It remains the top priority in antimicrobial-resistant *K. pneumoniae* due to high morbidity and mortality, limited treatment options, prolonged hospitalization, and high treatment costs (3-6). The Centers for Disease Control and Prevention (CDC) has classified it as one of the most “urgent” public health threats in the United States (7); according to the report of China Antimicrobial Resistance Surveillance System (CARSS), the resistant rate for the two main carbapenem antibiotics (imipenem and meropenem) has been steadily increasing from 2005 to 2017 (about 20%) (<http://www.chinets.com>).

Production of exogenous carbapenemases is one of the major causes for carbapenem resistance in KP, and carbapenemase-producing KP (cpKP) has emerged as a threatening epidemic pathogen in hospital settings (3, 8). The carbapenemase genes in cpKP mainly include *bla_{KPC}*, *bla_{NDM}*, and *bla_{IMP}*, of which *bla_{KPC}* is the most clinically significant one in most countries (3, 7). They are typically carried on the plasmids of many incompatibility (Inc) groups such as IncFII, X, I, C, N, R, P-2, U, W, and L/M(3, 9). *bla_{KPC}* on these plasmids are usually located on Tn4401b and its derivatives in European and American countries (9), but on Tn6296 and its derivatives in China (10). Tn4401b and Tn6296 are genetically wildly divergent, but both belong to Tn3-family unit transposons (9, 10).

Genomic studies showed that the clonal group CG258 is highly associated with cpKP isolates, especially *bla_{KPC}*-carrying cpKP (11-15). CG258 mainly consists of ST258 and its single-locus allelic variants ST11 and ST512. ST258 is a recombined hybrid from ST11 and ST442, which

contribute to the genome composition of ST258 by 80% and 20%, respectively (16). The cpKP isolates of ST258 and ST512 are mostly prevalent in American and European countries (9, 13, 17), while those of ST11 are highly dominant in China (18-20).

On the one hand, there are several publications to explore why ST258 cpKP successfully spread in USA and European countries (8, 21). On the other hand, although 115 STs of cpKP have been identified worldwide so far (9), it is reported that only ST11/CG258 has been successfully clonal spread in China (18-20). What is the cause of this phenomenon? Previous research only reported this phenomenon without deep mining the genetic basis (18-20). A large-scale genomic study on cpKP isolates is necessary to uncover the genetic basis for its dissemination in China, however, it is still lacking until now.

In this study, we employed second- and third-generation sequencing technologies to comprehensively analyze the genomic epidemiology in 420 clinical cpKP isolates collected from multicenter hospitals of 24 provinces of China from 2009 to 2017. The results displayed a panoramic population snapshot of cpKP isolates harboring mainly *bla*_{KPC}-carrying plasmids of diverse Inc groups and further provided essential insights into the evolution of host KP—*bla*_{KPC}-carrying plasmids and their role in facilitating the nationwide spread of ST11/CG258 cpKP.

Results

Genetic diversity of CG258 and non-CG258 cpKP from China

All the 420 cpKP isolates were sequenced using Illumina platform, and 69 of them were determined for complete genome sequences using PacBio (35/69) or Nanopore (34/69) sequencing platforms (Figure 1 and Table S1).

We first performed multilocus sequence typing (MLST; Figure 2a and Figure S1), and the results showed that 420 cpKP isolates were assigned into 48 STs, including six novel ones:

ST3333, ST3334, ST3345, ST3348, ST3349 and ST3350, which can further be assigned into four singletons and 31 CGs. Among those 420 cpKp isolates, CG258 and non-CG258 account for 313 and 107, respectively. Additionally, CG258 was the most prevalent CG (313/420, 74.52%) and composed of four STs: ST11 (298/313, 95.21%), ST2667 (7/313, 2.24%), ST3348 (6/313, 1.92%) and ST258 (2/313, 0.64%). Therefore, CG258 accounts for most of the cpKP isolates, and ST11 is the overwhelmingly dominant ST of CG258 in China.

We next analyzed the core-genome clustering in 2,300 global KP isolates, including our 420 cpKP isolates (Figure S2). Our 313 CG258 isolates were clustered with the other CG258 isolates, while our 107 non-CG258 isolates were scattered in the tree. Thus, in terms of genetic diversity, our 420 cpKP isolates showed good representativity.

We further performed the core-genome clustering analysis in our 420 cpKP isolates (Figure 2b). We found that the 313 CG258 isolates gathered at the farthest position from the root, suggesting CG258 was the latest clone different from other STs/CGs of cpKP. In contrast, the 107 non-CG258 isolates were located at earlier splitting branches in the tree and showed a highly dispersed pattern in the tree (containing several CGs), illustrating that they had an overall non-clonal population structure with a high level of genetic diversity.

Phylogeny and evolutionary history of CG258

Based on the analysis of whole-genome sequencing data, the 313 CG258 cpKP isolates had a total of 6,459 core single nucleotide polymorphisms (SNPs) with an inferred r/m ratio of 3.41, indicating the presence of frequent recombination. Moreover, recombination removal generated a final collection of 233 non-redundant CG258 cpKP isolates (225 of them belonged to ST11) with 1,271 recombination-free SNPs. Based on these SNPs, a time-calibrated Bayesian maximum clade credibility (MCC) tree (Figure 3a) showed that the CG258 cpKP isolates in China could be divided into three major clades: 1 to 3. Here the Clade 1 to Clade 3 isolates had

strong hospital and temporal diversity: the 23 Clade1 isolates were from 8 hospitals during 2010-2017; the 24 Clade 2 isolates were from 15 hospitals during 2011-2015; the 186 Clade3 isolates were from 42 hospitals during 2009-2017. These indicated that the formation of three major clades were not transmission events. Among the three clades, Clade 2 could be further discriminated into two subclades 2.1 and 2.2, and Clade 3 into three subclades 3.1 to 3.3. The emerging time-points of Clades 1, 2.1, 2.2, 3.1, 3.2 and 3.3 were in 1995, 2006, 2006, 2007, 2008 and 2010, respectively.

We further performed a Bayesian skyline plot (Figure 3b) based on the above 1,271 SNPs, and the results showed a strong population expansion of CG258 cpKP during 2007-2008, which was consistent with the estimated emergence stage of Clade 3. Notably, Clade 3 accounted for 79.8% (186/233) of the CG258 cpKP isolates, and, thus, it was the dominant lineage among the three clades. Therefore, this population expansion should represent the emergence and subsequent nationwide spread of the dominant Clade 3 of CG258 cpKP in China.

Prevalence of carbapenemase genes and *bla*_{KPC}-carrying plasmids

In the 420 cpKp isolates, we identified three kinds of carbapenemase genes, including *bla*_{KPC}-_{2/-3/-5} (375/420, 89.29%; especially *bla*_{KPC-2} in 372 isolates), *bla*_{NDM-1/-5} (29/420, 6.9%) and *bla*_{IMP-4/-38} (19/420, 4.52%) (Table S2). Most (309/375, 82.43%) of the *bla*_{KPC}-carrying isolates belong to CG258 and, meanwhile, *bla*_{KPC} was found in almost all (309/313, 98.72%) of the CG258 cpKP isolates. In contrast, the majority of the *bla*_{NDM}-carrying isolates (27/29, 93.10%) and the *bla*_{IMP}-carrying isolates (17/19, 89.47%) were assigned into non-CG258 (Table S3 and Figure S3). Thus, the dissemination of *bla*_{KPC}, as the most prevalent carbapenemase gene, was highly associated with the spread of CG258 cpKP isolates in China.

All the detected *bla*_{KPC} genes were located in plasmids. A total of 377 *bla*_{KPC}-carrying plasmids were identified from the 375 *bla*_{KPC}-harboring isolates with two isolates each carrying

a double copy of *bla_{KPC}* in two different plasmids. 79 of these 377 plasmids had the complete sequences (Table S1). These 377 plasmids could be assigned into 32 Inc groups, 20 (62.50%) of which had multiple replicons (Table S4). The top five Inc groups, including IncFII_{pHN7A8}:IncR (n=163), IncFII_{pHN7A8}:Inc_{pA1763-KPC} (n=59), IncFII_{pKPHS2}:Inc_{pA1763-KPC} (n=36), IncFII_{p0716-KPC}:Inc_{pA1763-KPC} (n=30) and IncFII_{pHN7A8} (n=28), accounted for 83.82% of all *bla_{KPC}*-harboring plasmids (Table S4). Each of top five Inc group had at least five complete plasmid sequences (Table S1, and Figure S4 to S8). The plasmids of each Inc group carried the identical core backbone *rep* (replication) and *par* (partition) genes but showed considerable modular divergence across whole plasmid genomes (Figure S4 to S8). Overall, the *bla_{KPC}*-harboring plasmids in cpKP isolates of China showed a high level of diversity, with the aforementioned top five Inc groups as the major types.

Notably, 62.50% (20/32) of Inc groups had a primary or single replicon belonging to the IncFII family, which accounted for a huge percentage of all plasmids (92.04%, 347/377) (Table S4). The IncFII replicons could be further divided into seven distinct sub-groups and displayed a high degree of genetic divergence, among which IncFII_{pHN7A8} (253/255, 99.22%) and IncFII_{p0716-KPC} (29/32, 90.63%) were highly associated with CG258. In contrast, IncFII_{pKPHS2} (35/42, 83.33%) was highly associated with non-CG258 (Figure S9).

The local *bla_{KPC}* genetic environments of the 377 *bla_{KPC}*-carrying plasmids could be divided into six major types: type 1 to type 6 (Figure S10). The former five types represented different derivatives of Tn6296 and accounted for 99.73% (376/377) of all plasmids, while type 6 was Tn4401b corresponding to the sole *bla_{KPC}*-carrying ST258 cpKP isolate.

Strong correlation between three major Inc groups of *bla_{KPC}*-carrying plasmids and CG258

IncFII_{pKPHS2}:Inc_{pA1763-KPC} and the other four top Inc groups of plasmids were highly associated

with non-CG258 and CG258, respectively (Figure 4a). Firstly, 91.67% (33/36) of the *bla*_{KPC}-carrying IncFII_{pKPHS2}:Inc_{pA1763-KPC} plasmids came from non-CG258 involving 11 STs that could be further assigned into nine CGs (Table S3), indicating a highly dispersed dissemination of IncFII_{pKPHS2}:Inc_{pA1763-KPC} plasmids among a lot of non-CG258 subtypes.

Secondly, 98.93% (277/280) of the other four top Inc groups of *bla*_{KPC}-carrying plasmids corresponded to 88.50% of the CG258 cpKP isolates (277/313). In addition, we also downloaded 38 complete genomes of ST11/CG258 cpKP isolates from NCBI, and 77.5% ST11/CG258 cpKP isolates harbored the four Inc groups of plasmids (Table S5). Previous studies also demonstrated the strong association between ST11/CG258 cpKP and the four Inc groups of plasmids of IncFII-like plasmids (8, 21).

Moreover, different Inc groups of *bla*_{KPC}-carrying plasmids had strongly correlated with various clades of CG258 (Figure 4b). We observed a strong correlation of IncFII_{pHN7A8} (13/13, 100%)+IncFII_{pHN7A8}:IncR (119/122, 97.54%), IncFII_{pHN7A8}:Inc_{pA1763-KPC} (45/45, 100%), and IncFII_{p0716-KPC}:Inc_{pA1763-KPC} (23/23, 100%) with Clade 3.1+3.2, Clade 3.3, and Clade 2.2+an unnamed subclade of Clade 1, respectively (Figure 4b). And vice versa, Clade 3.1 +3.2 (132/136, 97.06%), Clade 3.3 (45/47, 95.74%), and Clade 2.2+an unnamed subclade of Clade 1 (23/28, 82.14%) showed a higher correlation with IncFII_{pHN7A8}+IncFII_{pHN7A8}:IncR, IncFII_{pHN7A8}:Inc_{pA1763-KPC}, and IncFII_{p0716-KPC}:Inc_{pA1763-KPC}, respectively (Figure 4b). In addition, we obtained four nonsynonymous and eight synonymous SNPs for discriminating Clade 2+3 from Clade 1, and one nonsynonymous and four synonymous SNPs for differentiating Clade 3 from the other two clades (Figure 4b), indicating the potential markers for accurate classification of various types of CG258 cpKP isolates.

Acquisition of three IncFII_{pHN7A8}—related Inc groups of *bla*_{KPC}-carrying plasmids promoted nationwide spread of CG258

As described above, Clade 3 represented the dominant lineage of the nationwide spread CG258 cpKP in China. Almost all the Clade 3 isolates (180/186, 96.77%) contained the *bla*_{KPC}-carrying plasmids of three IncFII_{pHN7A8}-related Inc groups, including IncFII_{pHN7A8}, IncFII_{pHN7A8}:IncR, and IncFII_{pHN7A8}:Inc_{pA1763-KPC} (Figure 4), which also belonged to the above top five Inc groups. This finding suggests that these three IncFII_{pHN7A8}-related Inc groups had phenotypic advantages relative to the other two top Inc groups.

We next examined the susceptibility/resistance profiles of 420 cpKp isolates to nine distinct classes of 21 different antibiotics (Figure S11, and Table S1). The capability of resistance to different antibiotic classes had the following tendency (high to low): the 249 CG258 isolates harboring the *bla*_{KPC}-carrying plasmids of the three IncFII_{pHN7A8}-related Inc groups > the 28 CG258 isolates harboring those of IncFII_{p0716-KPC}:Inc_{pA1763-KPC} > the 33 non-CG258 isolates harboring those of IncFII_{pKPHS2}:Inc_{pA1763-KPC} (Figure 5a). This trend was also observed when the bacterial growth rates under antibiotic treatment were compared among the above groups of isolates (Figure 5b). In addition, we chose five representative *bla*_{KPC}-carrying cpKP isolates each containing a single plasmid: G134 (ST11+IncFII_{pHN7A8}), G285 (ST11+IncFII_{pHN7A8}:IncR), G318 (ST11+IncFII_{pHN7A8}:Inc_{pA1763-KPC}), G165 (ST11+IncFII_{p0716-KPC}:Inc_{pA1763-KPC}) and G344 (non-CG258+IncFII_{pKPHS2}:Inc_{pA1763-KPC}) for *in vitro* competitive assay. The results showed a similar tendency: the three IncFII_{pHN7A8}-related Inc groups > IncFII_{p0716-KPC}:Inc_{pA1763-KPC} > IncFII_{pKPHS2}:Inc_{pA1763-KPC} (Figure 5c). Therefore, in relative to IncFII_{p0716-KPC}:Inc_{pA1763-KPC} and IncFII_{pKPHS2}:Inc_{pA1763-KPC}, the acquisition of three IncFII_{pHN7A8}-related Inc groups of *bla*_{KPC}-carrying plasmids rendered their host KP higher levels of antibiotic resistance, growth, and competition advantages. These phenotypic advantages might promote the nationwide spread of the dominant Clade 3 of CG258 cpKP in China.

Optimized antibiotic combination regimens for cpKP treatment

All of the cpKP isolates were resistant to β -lactams including carbapenems, whereas the resistant rates of these isolates to aminoglycosides [amikacin (47.86%, 201/420), tobramycin (57.62%, 242/420) and gentamicin (79.52%, 334/420)] and trimethoprim/sulfamethoxazole (65%, 273/420) were much lower (Figure S11a). For each of the ten antibiotics tested (Figure S11b), CG258 isolates displayed a much higher drug resistance rate than non-CG258. As shown by the number of antibiotic classes that the isolates were resistant to, CG258 showed much higher resistance levels than non-CG258 (Figure S12). Specifically, CG258 had the lowest resistance rates for amikacin (57.4%, 179/312) followed by trimethoprim/sulfamethoxazole (67.7%, 212/313) and tobramycin (73.2%, 202/276), while non-CG258 exhibited the lowest resistance for amikacin (20.6%, 22/107) followed by tobramycin (50.6%, 40/79) and levofloxacin (53.9%, 55/102) (Figure S11b). This large discrepancy of resistance profile between CG258 and non-CG258 led us to optimize the antibiotic combination regimens to treat CG258 and non-CG258.

Based on the calculated resistance ratios when different two-antibiotics combination regimens were used for CG258 treatment, two optimized combinations of ‘amikacin+trimethoprim/sulfamethoxazole’ and ‘tobramycin+trimethoprim/sulfamethoxazole’ produced the resistance ratios of 32.59% (102/313) and 39.62% (124/313), respectively, which were much lower than the ratio of 57.4% (179/312) calculated for single-antibiotic ‘amikacin’ (Figure 6a). In addition, the combinations of ‘amikacin+macrodantin’ and ‘amikacin+cefotetan’ represented the two optimized two-antibiotics combination for non-CG258 treatment, with the resistance ratios of 13.08% (14/107) and 14.02% (15/107), respectively (Figure 6b).

Discussion

This study primarily revealed that the three host-plasmid ‘golden’ combinations played an important and even decisive role in the successfully clonal spread and dissemination of

ST11/CG258 cpKp in China. Here the three host-plasmid ‘golden’ combinations indicate the three main phylogenetic subclades of ST11/CG258 cpKp isolates carrying the three most prevalent Inc groups of KPC-producing plasmids: Clade 3.1+Clade 3.2 — IncFII_{PHN7A8}, Clade 3.1+Clade 3.2 — IncFII_{PHN7A8}:IncR, Clade 3.3 — IncFII_{PHN7A8}:Inc_{PA1763}-KPC (Figure 3b and Figure 4b). We name them “golden combinations” due to the genotypic and phenotypic advantages of these isolates. On the one hand, our findings illustrated the genotypic advantages of the three host-plasmid ‘golden’ combinations in strong correlation and coevolution (Figure 3a and Figure 4b); on the other hand, we demonstrated the phenotypic advantages of the three ‘golden’ combinations in drug-resistance, growth and competition (Figure 5). The genotypic and phenotypic advantages of the three host-plasmid ‘golden’ combinations are reciprocal causation, which improve the adaptability of the three IncFII_{PHN7A8} families of plasmids to ST11/CG258 cpKp isolates, further leading to their successfully clonal spread and dissemination in China. Overall, they form a closed-loop process: the genotypic and phenotypic advantages of three host-plasmid ‘golden’ combinations, and their successful spread and dissemination in China (Figure 7).

Three ‘golden’ combinations of host KP—*bla*_{KPC}-carrying plasmid constitutes the major genetic basis (main internal cause) for the nationwide spread of ST11/CG258 cpKP in China

Most cpKP isolates in China belong to the clonal group CG258 with ST11 as the dominant ST. In contrast, non-CG258 isolates had an overall non-clonal population structure with very high levels of genetic diversity. Our core-genome phylogenetic analysis identified Clade 3 as the dominant lineage. On the other hand, *bla*_{KPC} was the dominant carbapenemase gene located in the plasmids of cpKP isolates. Among the five major Inc groups of *bla*_{KPC}-harboring plasmids, a strong correlation of IncFII_{PHN7A8}+IncFII_{PHN7A8}:IncR, IncFII_{PHN7A8}:Inc_{PA1763}-KPC, and

IncFII_{p0716-KPC}:Inc_{pA1763-KPC} with CG258 Clade 3.1+3.2, Clade 3.3, and Clade 2.2+an unnamed subclade of Clade 1, respectively, were observed, while IncFII_{pKPHS2}:Inc_{pA1763-KPC} was highly associated with non-CG258.

The dissemination of CG258 cpKP in China was characteristic of a nationwide spread of the dominant Clade 3 since 2007-2008 (Figure 3b). A strong population expansion was observed for CG258 cpKP during 2007-2008, which was accompanied by the emergence of two host-plasmid ‘golden’ combinations at the same period: Clade 3.1+Clade 3.2 — IncFII_{pHN7A8}, Clade 3.1+Clade 3.2 —IncFII_{pHN7A8}:IncR. In addition, the host-plasmid ‘golden’ combination, Clade 3.3 — IncFII_{pHN7A8}:Inc_{pA1763-KPC} emerged at 2010. The expanded CG258 population retained at a high level with limited dynamic fluctuation, which was linked to the spread of Clade 3.1+3.2 since 2007-2008 as well as that of Clade 3.3 since 2010 (Figure 3b and Figure 7).

Acquisition of *bla*_{KPC}-carrying plasmids of IncFII_{pHN7A8}, IncFII_{pHN7A8}:IncR, and IncFII_{pHN7A8}:Inc_{pA1763-KPC} endowed their host KP isolates with phenotypes of a higher competitive growth rate and more antibiotic resistance, relative to those harboring IncFII_{p0716-KPC}:Inc_{pA1763-KPC} or IncFII_{pKPHS2}:Inc_{pA1763-KPC} (Figure 5). Remarkably, the evolution of three ‘golden’ combinations of host CG258—*bla*_{KPC}-carrying plasmid (Clade 3.1+3.2—IncFII_{pHN7A8}, Clade 3.1+3.2—IncFII_{pHN7A8}:IncR, and Clade 3.3—IncFII_{pHN7A8}:Inc_{pA1763-KPC}) rendered them phenotypic advantages that might directly lead to their strong expansion and subsequent clonal dissemination since 2007-2008 in China.

In particular, more attention should be paid to the following two ‘golden’ combinations: Clade 3.1+3.2—IncFII_{pHN7A8}:IncR, and Clade 3.3—IncFII_{pHN7A8}:Inc_{pA1763-KPC}, as they were ranked at the first (58.84%, 163/277) and second (20.94%, 58/277) percentages of CG258 cpKP isolates, respectively, and positioned at the farthest point from the root of the phylogenetic tree of CG258 cpKP isolates. Thus, they might represent the latest differentiation events and have the best host KP—plasmid adaptability, therefore, emerge as the highest risk lineages.

IncFII_{pHN7A8}:IncR or IncFII_{pHN7A8}:Inc_{pA1763-KPC} plasmids are the chimeras of IncFII_{pHN7A8} plasmids (carrying *bla*_{KPC}) and IncR/Inc_{pA1763-KPC} plasmids (carrying multiple resistance genes) (22-25). Compared to single-replicon plasmids, multi-replicon plasmids have the advantages of rapid replication, replicon substitution, multiple partitioning and/or toxin-antitoxin systems for plasmid maintenance, and a high survival rate. The above two chimeric plasmids also possess additional unique advantages: i) IncR or Inc_{pA1763-KPC} backbones are very small, giving the low adaptability costs of the chimeras after their fusion with IncFII_{pHN7A8}; ii) IncR or Inc_{pA1763-KPC} plasmids carried large multidrug resistance regions, expanding the resistance profile of their hosts; and iii) although IncR or Inc_{pA1763-KPC} plasmids did not carry conjugation transfer regions, they can obtain self-transfer ability after fusion with conjugative IncFII_{pHN7A8} plasmids, further facilitating the spread of resistance genes they carried.

Widespread use of carbapenems is the leading external cause for the expansion and prevalence of ST11/CG258 cpKp in China.

Bacterial antibiotic resistance as a serious threat to public health is of the greatest concern in China. In addition to the genetic basis of three ‘golden’ combinations accounting for the population size change of CG258 cpKP, rapidly increased sales/use of carbapenems since 2005 with the highest growth rate during 2007-2008 (Figure S13) constitutes the major external force driving antibiotic resistance, clonal expansion and consequently nationwide spread of ST11/CG258 cpKP in China.

Specifically, the consumption of Meropenem (a common carbapenem antibiotic) increased sharply from 2007 to 2009 (Figure S13). At the same period, some other carbapenems were listed in China and also facilitated their consumption (ertapenem: 2005, faropenem: 2006, biapenem: 2008). Overall, the rapid growth of carbapenem consumption around 2007 might directly led to the expansion of ST11/CG258 cpKP population. After 2007-08, the expansion of

cpKP population was restrained and entered a plateau (Figure 3a), which was mainly due to the slow growth of sales of carbapenems in China. Along with imposing restrictions on antibiotic prescription issued by the Ministry of Health of China since 2011, it has been reported that the use of antibiotics in many hospitals across the country has decreased significantly (26, 27). In addition, the Chinese government has introduced several policies to strictly control the usage of carbapenem antibiotics covering 1,429 hospitals (<http://www.chinets.com>).

In conclusion, the population change of ST11/CG258 cpKp isolates in China might be derived from the internal cause (three host-plasmid ‘golden’ combinations) and the external cause (widespread use of carbapenems). Exogenous variables could result in endogenous changes, and they worked together to facilitated the spread and prevalence of ST11/CG258 cpKP isolates in China. Internal monitoring and external control should effectively inhibit the epidemic spread of cpKP isolates.

Possibility of precision medication in clinic cpKP treatment

Based on the susceptibility/resistance phenotypes to nine distinct classes of 21 different antibiotics, cpKP isolates in China displayed the lowest resistance rates for three aminoglycosides (amikacin, tobramycin, gentamicin) and trimethoprim/sulfamethoxazole. Similar results have also been reported in a wealth of literature (Table S6). Additionally, our findings revealed that CG258 cpKP has much broader resistance profiles than non-CG258 cpKP (Figure S12), which is supported by the epidemiological survey data of carbapenem-resistant *Enterobacteriaceae* from 2012 to 2016 in China (19). These findings make the possibility to optimize the two-antibiotics combination regimens for treatment of CG258 and non-CG258 through calculating their resistance ratios when different antibiotic combinations are used. More importantly, cpKP with three ‘golden’ combinations showed the highest resistance profiles than other cpKP. More in-depth studies on different antibiotic combination regimens need to be executed for various cpKP genotypes with different Inc groups of plasmids, which will provide

a precise reference and a choice to treat cpKP infection by using the existing drugs effectively.

Eventually, we hope that our study can appeal for people to closely monitor the adaptability of resistant plasmids, so as to effectively prevent the emergence/dissemination of new ‘golden’ host-plasmid combinations. Additionally, we should consider both genotypes (isolates) and Inc groups (drug-resistant plasmids) to achieve precision medication of cpKp infections.

Materials and Methods

Bacterial isolates and genomic DNA extraction

We collected 2,803 clinical *K. pneumoniae* isolates from 70 hospitals in 24 provinces of China from 2009 to 2017. After eliminating 59 culture failed isolates, 2,744 isolates were obtained for PCR detection of *K. pneumoniae*-specific *khe* gene to identify the species. After excluding the 53 isolates without *khe* gene, 2,691 isoates were further tested to produce carbapenemases by Modified Carba NP test: 493 isolates were confirmed to produce carbapenemases. Bacterial genomic DNAs were then extracted using a Qiagen UltraClean Microbial DNA Isolation Kit, which were sequenced by Illumina technology. After excluding 73 low-quality sequencing sample, 420 cpKP genomes were used for the subsequent analysis (Table S1).

Genome sequencing and assembly

The draft genome sequences of bacterial genomic DNA were sequenced from a paired-end library with an average insert size of 350 bp on an Illumina HiSeq2000 sequencing platform (28). Adapters and low-quality reads were removed using *FASTX-Toolkit* (http://hannonlab.cshl.edu/fastx_toolkit/). *SPAdes* v3.9.0 (29) was used to do the *de novo* assembly from the trimmed sequence reads using *k*-mer sizes of 21, 33, 55 and the -cov-cutoff flag set to ‘auto’. Isolates were discarded through the following analyses: i) if the size of the *de novo* assembly was outside of 5-7 Mb, ii) if the average nucleotide identity to NJST258_1 was

lower than 95% or the top match was not NJST258_1 after the *de novo* assembly was compared with the reference genomes of five *Klebsiella* spp. (*K. pneumoniae* NJST258_1, CP006923; *K. quasipneumoniae* ATCC 700603, CP014696; *K. michiganensis* E718, NC_018106; *K. oxytoca* CAV1374, CP011636; *K. variicola* DSM 15968, CP010523) using *Pyani-0.2.7* (30), and iii) if the percentage of the total number of genomic sites with more than 10-fold depth of coverage was lower than 80% after the raw sequencing reads of each isolate were mapped to the NJST258_1 genome using *Bowtie2* (31) and the depth of coverage for each position on the genome were calculated using *samtools depth* v0.1.19 (32).

The complete genome sequences was obtained from a sheared DNA library with an average size of 10 kb on a PacBio RSII sequencer (Pacific Biosciences) (33), and the *de novo* sequence assembly was performed using *SMRT Analysis* v2.3.0 (<https://smrt-analysis.readthedocs.io/en/latest/>). Nanopore GridION platform was also used for whole-genome sequencing (34), and the high-quality reads (mean_qscore_template ≥ 7 and length $\geq 1,000$) were screened for further *de novo* sequence assembly using *canu* (<https://canu.readthedocs.io/en/latest/>) (35). Circularization of chromosomal or plasmid sequences was achieved by manual comparison. *Pilon* v.1.13 (36) was employed to polish complete genome sequences using Illumina sequencing reads.

MLST

SRST2 (37) was used to identify the ST of each KP isolate by mapping its Illumina sequencing reads to the Pasteur *Klebsiella* MLST Database (<http://bigsd.b.pasteur.fr/klebsiella/klebsiella.html>). All the STs in the *Klebsiella* MLST database (last accessed August 3, 2018) were assigned to different CGs using *eBURST* (38).

Construction of maximum-likelihood clustering trees

Chromosome sequences were mapped to a reference sequence of NJST258_1 (11) using *Bowtie2* (31). The core SNPs of the 2,300 global KP isolates were identified using *Mummer* v3.25 (39), and the core SNPs of our 420 cpKp isolates were called using *GATK Unified Genotyper* (40). We filtered all the SNPs in the repetitive DNA regions (identified by *RepeatMasker*, <http://www.repeatmasker.org/>) and the mobile genetic elements (including insertion sequences, transposons, integrons, and phage-related genes). Based on the above core SNPs, the maximum-likelihood clustering trees of the 2,300 global KP isolates and our 420 cpKp isolates were constructed using *FastTree* V2.1.9 (41) and *RAxML* (42), respectively (Bootstrap value: 500).

Construction of recombination-free Bayesian phylogenetic tree

Our 313 CG258 cpKP isolates were subjected to sequence alignment. Recombination DNA regions were predicted using *ClonalFrameML* (43), followed by removal of all putative recombinant SNP sites. A Bayesian phylogenetic tree was constructed from the recombination-free core SNPs of the resulting 233 non-redundant CG258 cpKP isolates using *MrBayes* (44) and visualized using *iTOL* (<https://itol.embl.de/>).

Bayesian phylogenetic inference and molecular dating analyses

Bayesian skyline analysis was performed to calculate the change in the effective population size of the above 233 isolates using *BEAST* v1.8.4 (45). The three standard substitution models, Hasegawa-Kishino-Yano (HKY), general time-reversible (GTR), and Tamura-Nei 93 (TN93) was tested in combination with the estimated/empirical base frequency, the gamma (G) site heterogeneity and the loose molecular clock. By testing various parameter combinations, the model combination GTR+empirical+G4 was selected. The tip date was defined as the sampling time. In the end, three independent chains of 5×10^7 generations were run to ensure calculation

accuracy, with sampling every 1,000 iterations. The resulting Bayesian skyline plot was visualized using *Tracer* v1.7 (46). A time-calibrated Bayesian MCC tree of the above 233 isolates was constructed using *TreeAnnotator* (<https://beast.community/treeannotator>) and visualized using *FigTree* (<http://tree.bio.ed.ac.uk/software/figtree/>).

Plasmid analysis

All the fully sequenced *bla*_{KPC}-carrying plasmids from GenBank (last accessed Aug 29, 2018) and our study were used as the references. The draft sequences of the rest *bla*_{KPC}-carrying plasmids in our 420 cpKp isolates were aligned using *BLAST* (47) and custom *Perl* scripts. Inc groups and core backbone *rep* and *par* genes were determined for all the *bla*_{KPC}-carrying plasmids in our 420 cpKp isolates. To ensure accuracy, the assembled draft plasmid sequences met the following three criteria (48): the *bla*_{KPC}-embedded contigs had 100% query coverage and $\geq 99\%$ identity with corresponding reference plasmids; the *bla*_{KPC}-embedded contigs and the *rep*-embedded contigs of the same plasmid had similar sequencing depths; each draft plasmid sequence had $\geq 70\%$ Query coverage and $\geq 94\%$ identity with corresponding reference plasmids.

Identification of carbapenemase genes

The major plasmid-borne carbapenemase genes were screened for each cpKP isolate by PCR, followed by amplicon sequencing using ABI 3730 Sequencer (49). The variants of *bla*_{KPC}, *bla*_{NDM}, and *bla*_{IMP} were identified from genome sequence data using *ResFinder* (50).

Bacterial phenotypic resistance assays

Bacterial antimicrobial susceptibility was tested by BioMérieux VITEK 2 and interpreted based on the 2018 Clinical and Laboratory Standards Institute (CLSI) guidelines (51). The activity of

Ambler class A/B/D carbapenemases in bacterial cell extracts was determined by a modified CarbaNP test (49).

Bacterial growth curves

Bacterial growth curves were measured on a 96 well-microtitre plate using a Thermo Scientific Multiskan FC instrument. Equivalent amount of overnight bacterial culture was inoculated in each well containing 200 µl of LB liquid medium (4 mg/L meropenem), and the mixtures were cultured at 37°C overnight with a speed of 5 Hz. The bacterial growth curve was determined through a course of time by recording the turbidity at 600 nm using the microplate reader of the Multiskan FC instrument. Experiments were performed in triplicate.

***In vitro* competition experiments**

Equivalent amount of overnight bacterial cultures of two indicated bacterial isolates were inoculated into 10 ml of LB liquid medium (4 mg/L meropenem), and the mixtures were cultured at 37°C for 72 h in a shaker with a speed of 200 rpm. At 0, 24, 48, and 72h, 3 mL aliquots of the cultures were taken, and genomic DNAs were extracted. To examine the competition between two bacterial isolates, real-time qPCRs were performed to determine the ratio of Ct values between each of the four ST11/CG258 isolates (G134, G285, G318, and G165) and the control non-CG258 isolate G344. The five genes G134_05212, G285_01367, G318_02254, G165_02217, and G344_00764 were selected as PCR target sequences, and the corresponding PCR primers were listed in Table S7. Experiments were performed in triplicate.

Data availability

The genome sequences in this study were submitted to Genome Sequence Archive under accession number CRA003059. Individual accession numbers for sequence data were also

available in Table S1.

Author Contributions

DZ and FC conceived the study. CL and TY performed the bioinformatics analyses. XJ, YJ, LY, GM, ZY, YJ, XL, and XW carried out the experimental analyses. CL, XJ, TY, XY, and SL drew the figures. DZ, FC, and CL wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by National Key R&D Program of China (2018YFC1200100), National Science and Technology Major Project of China (2018ZX10302-301-004-003), and National Natural Science Foundation of China (31770870).

Competing interest statement

The authors declare no competing interests.

484

References

- 485 1. De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial
486 resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33(3).
- 487 2. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant *Klebsiella pneumoniae*: the
488 state of the art. Expert Rev Anti Infect Ther. 2013;11(2):159-77.
- 489 3. Tzouvelekis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella*
490 *pneumoniae* and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev.
491 2012;25(4):682-707.
- 492 4. Nordmann P, Cuzon G, Naas T. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria.
493 Lancet Infect Dis. 2009;9(4):228-36.
- 494 5. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and
495 prevention. Clin Infect Dis. 2011;53(1):60-7.
- 496 6. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and
497 development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet
498 Infect Dis. 2018;18(3):318-27.
- 499 7. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology
500 of the global expansion of *Klebsiella pneumoniae* carbapenemases. Lancet Infect Dis. 2013;13(9):785-96.
- 501 8. David S, Cohen V, Reuter S, Sheppard AE, Giani T, Parkhill J, et al. Integrated chromosomal and plasmid
502 sequence analyses reveal diverse modes of carbapenemase gene spread among *Klebsiella pneumoniae*. Proc Natl
503 Acad Sci U S A. 2020;117(40):25043-54.
- 504 9. Chen L, Mathema B, Chavda KD, DeLeo FR, Bonomo RA, Kreiswirth BN. Carbapenemase-producing
505 *Klebsiella pneumoniae*: molecular and genetic decoding. Trends Microbiol. 2014;22(12):686-96.
- 506 10. Li B, Feng J, Zhan Z, Yin Z, Jiang Q, Wei P, et al. Dissemination of KPC-2-Encoding IncX6 plasmids among
507 multiple Enterobacteriaceae species in a single Chinese hospital. Front Microbiol. 2018;9:478.
- 508 11. Deleo FR, Chen L, Porcella SF, Martens CA, Kobayashi SD, Porter AR, et al. Molecular dissection of the
509 evolution of carbapenem-resistant multilocus sequence type 258 *Klebsiella pneumoniae*. Proc Natl Acad Sci U S
510 A. 2014;111(13):4988-93.
- 511 12. Rojas LJ, Weinstock GM, De La Cadena E, Diaz L, Rios R, Hanson BM, et al. An Analysis of the epidemic
512 of *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: convergence of two evolutionary
513 mechanisms creates the "Perfect Storm". J Infect Dis. 2017;217(1):82-92.
- 514 13. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of carbapenem-resistant
515 *Klebsiella pneumoniae* in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4(11):1919-29.
- 516 14. Arena F, Di Pilato V, Vannetti F, Fabbri L, Antonelli A, Coppi M, et al. Population structure of KPC
517 carbapenemase-producing *Klebsiella pneumoniae* in a long-term acute-care rehabilitation facility: identification
518 of a new lineage of clonal group 101, associated with local hyperendemicity. Microb Genom. 2020;6(1).
- 519 15. Dong N, Zhang R, Liu L, Li R, Lin D, Chan EW, et al. Genome analysis of clinical multilocus sequence Type
520 11 *Klebsiella pneumoniae* from China. Microb Genom. 2018;4(2).
- 521 16. Chen L, Mathema B, Pitout JD, DeLeo FR, Kreiswirth BN. Epidemic *Klebsiella pneumoniae* ST258 is a
522 hybrid strain. mBio. 2014;5(3):e01355-14.
- 523 17. Wyres KL, Holt KE. *Klebsiella pneumoniae* population genomics and antimicrobial-resistant clones. Trends
524 Microbiol. 2016;24(12):944-56.
- 525 18. Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. ST11, the dominant clone of KPC-producing *Klebsiella pneumoniae*
526 in China. J Antimicrob Chemother. 2011;66(2):307-12.
- 527 19. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, et al. Phenotypic and genotypic characterization of

carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012-2016). Clin Infect Dis. 2018;67(suppl_2):S196-S205.

20. Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98-106.

21. Stoesser N, Phan HTT, Seale AC, Aiken Z, Thomas S, Smith M, et al. Genomic epidemiology of complex, multispecies, plasmid-borne *bla*_{KPC} carbapenemase in Enterobacterales in the United Kingdom from 2009 to 2014. Antimicrob Agents Chemother. 2020;64(5).

22. Qu D, Shen Y, Hu L, Jiang X, Yin Z, Gao B, et al. Comparative analysis of KPC-2-encoding chimera plasmids with multi-replicon IncR:IncA1763-KPC:IncN1 or IncFIIpHN7A8:IncA1763-KPC:IncN1. Infect Drug Resist. 2019;12:285-96.

23. He L, Partridge SR, Yang X, Hou J, Deng Y, Yao Q, et al. Complete nucleotide sequence of pHN7A8, an F33:A-B- type epidemic plasmid carrying blaCTX-M-65, fosA3 and rmtB from China. J Antimicrob Chemother. 2013;68(1):46-50.

24. Shi L, Feng J, Zhan Z, Zhao Y, Zhou H, Mao H, et al. Comparative analysis of blaKPC-2- and rmtB-carrying IncFII-family pKPC-LK30/pHN7A8 hybrid plasmids from Klebsiella pneumoniae CG258 strains disseminated among multiple Chinese hospitals. Infect Drug Resist. 2018;11:1783-93.

25. Jing Y, Jiang X, Yin Z, Hu L, Zhang Y, Yang W, et al. Genomic diversification of IncR plasmids from China. J Global Antimicrob Resist. 2019;19:358-64.

26. Bao L, Peng R, Wang Y, Ma R, Ren X, Meng W, et al. Significant reduction of antibiotic consumption and patients' costs after an action plan in China, 2010-2014. PLoS One. 2015;10(3):e0118868.

27. Sun J, Shen X, Li M, He L, Guo S, Skoog G, et al. Changes in patterns of antibiotic use in Chinese public hospitals (2005-2012) and a benchmark comparison with Sweden in 2012. J Glob Antimicrob Resist. 2015;3(2):95-102.

28. Ribeiro FJ, Przybylski D, Yin S, Sharpe T, Gnerre S, Abouelleil A, et al. Finished bacterial genomes from shotgun sequence data. Genome Res. 2012;22(11):2270-7.

29. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19(5):455-77.

30. Pritchard L, Glover RH, Humphris S, Elphinstone JG, Toth IK. Genomics and taxonomy in diagnostics for food security: soft-rotting enterobacterial plant pathogens. Analytical Methods. 2016;8(1):12-24.

31. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357-9.

32. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-9.

33. Zhu L, Zhong J, Jia X, Liu G, Kang Y, Dong M, et al. Precision methylome characterization of Mycobacterium tuberculosis complex (MTBC) using PacBio single-molecule real-time (SMRT) technology. Nucleic Acids Res. 2016;44(2):730-43.

34. Jain M, Olsen HE, Paten B, Akeson M. The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community. Genome Biol. 2016;17(1):239.

35. Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Res. 2017;27(5):722-36.

36. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS One. 2014;9(11):e112963.

37. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, et al. SRST2: Rapid genomic surveillance for public health and hospital microbiology labs. Genome Med. 2014;6(11):90.

38. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. eBURST: inferring patterns of evolutionary descent

among clusters of related bacterial genotypes from multilocus sequence typing data. *J Bacteriol.* 2004;186(5):1518-30.

39. Bortz DM, Jackson TL, Taylor KA, Thompson AP, Younger JG. *Klebsiella pneumoniae* flocculation dynamics. *Bull Math Biol.* 2008;70(3):745-68.

40. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010;20(9):1297-303.

41. Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. *Mol Biol Evol.* 2009;26(7):1641-50.

42. Stamatakis A. RAXML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. *Bioinformatics.* 2006;22(21):2688-90.

43. Didelot X, Wilson DJ. ClonalFrameML: efficient inference of recombination in whole bacterial genomes. *PLoS Comput Biol.* 2015;11(2):e1004041.

44. Ronquist F, Teslenko M, van der Mark P, Ayres DL, Darling A, Hohna S, et al. MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space. *Syst Biol.* 2012;61(3):539-42.

45. Suchard MA, Lemey P, Baele G, Ayres DL, Drummond AJ, Rambaut A. Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol.* 2018;4(1):vey016.

46. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior Summarization in Bayesian Phylogenetics Using Tracer 1.7. *Syst Biol.* 2018;67(5):901-4.

47. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. *BMC Bioinformatics.* 2009;10:421.

48. Cerqueira GC, Earl AM, Ernst CM, Grad YH, Dekker JP, Feldgarden M, et al. Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. *Proc Natl Acad Sci U S A.* 2017;114(5):1135-40.

49. Feng J, Qiu Y, Yin Z, Chen W, Yang H, Yang W, et al. Coexistence of a novel KPC-2-encoding MDR plasmid and an NDM-1-encoding pNDM-HN380-like plasmid in a clinical isolate of *Citrobacter freundii*. *J Antimicrob Chemother.* 2015;70(11):2987-91.

50. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother.* 2012;67(11):2640-4.

51. CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

Figures

Fig. 1|Spatial-temporal distribution of cpKP isolates from China. a, Distribution of our 420 cpKP isolates in different provinces. **b**, Distribution of the 420 cpKP isolates in different years and hospitals. The red circles (a) and color palettes (b) indicated the numbers of isolates. Hospital H1 to H70 (b) could be assigned to different provinces in different colors.

610

611 **Fig. 2|MLST and clustering tree of cpKP isolates. a**, A profile of STs, CGs, and singletons of our 420 cpKP isolates. These 420 isolates consisted
612 of 313 CG258 ones and 107 non-CG258 ones. The six novel STs identified in this study were highlighted in red. **b**, A maximum-likelihood
613 clustering tree based on the 69,880 core SNPs of the 420 cpKP isolates. *K. variicola* isolate DSM 15968 was used as the outgroup but not shown

614 in the tree. The outer and inner circles in the tree indicated CGs and STs, respectively.

Fig. 3|Evolutionary history of CG258 cpKP isolates. a, A time-calibrated MCC Bayesian phylogeny based on the 1,271 recombination-free core SNPs. These SNPs came from our 233 non-redundant CG258 cpKP isolates that were shrunk from the total collection of 313 CG258 cpKP ones (see main text). The isolates carrying different Inc groups of blaKPC-carrying plasmids were denoted as distinct colored clusters in the tree. **b,** A Bayesian skyline of the effective population size of the 233 CG258 cpKP isolates. Shadow region indicated 95% probability density interval of estimated population size.

Fig. 4|Correlation of different Inc groups of *bla*_{KPC}-carrying plasmids with CG258 and non-CG258. a, Prevalence of the top five Inc groups (Table S4) among our CG258 and non-CG258 cpKp isolates. The numbers in the cells represented numbers of cpKp isolates (316 in total). b, Association of the four Inc groups with different clades of CG258. The tree was the Bayesian tree of the 233 CG258 cpKp isolates. The SNPs on the nodes indicated some specific markers for the accurate classification of Clade 1, 2, and 3 of ST11/CG258 cpKP isolates.

Fig. 5| Resistance, growth, and competition advantages of cpKP harboring *bla*_{KPC}-carrying plasmids of different Inc groups. a, Boxplots showed the numbers of classes of antibiotics that different subgroups of cpKP isolates were resistant to. The *p* values were obtained using Kruskal-Wallis, a non-parametric test for the comparison of multiple groups. ***, statistically significant with $p < 0.0001$. **b,** Bacterial growth curves of different subgroups of cpKP isolates. The dashed line indicated the timepoint at 1 h, when bacteria were at the logarithmic growth phases; corresponding *OD*₆₀₀ values (mean ± standard error) were shown in the embedded bar-plot. **c,** Bacterial *in vitro* competition experiments. Shown were the Ct value ratios (mean ± standard error) between each two cpKP isolates at 24h, 48h, and 72h, respectively.

a

b

Fig. 6| Optimized two-antibiotics combination regimens for treatment of CG258 and non-CG258. Shown were the resistance ratios (the numbers of isolates resistant to both antibiotics tested/the total numbers of isolates) when different two-antibiotics combination regimens were used for the treatment of CG258 (a) and non-CG258 (b). The drug resistance ratio of each two different drug combinations of 11 antibiotics

645 (excluding 10 antibiotics with the resistance ratio of ~100% and some banned drug combinations) was calculated. The size of the solid circles
646 increases with the increase in resistance ratio. The red rectangle indicates the optimized drug combinations of two drugs. The red cross indicates
647 the prohibited drug combinations since they belong to the same type of antimicrobial drug.

648

Fig. 7| Three 'golden' host—plasmid combinations. The three 'golden' host—plasmid combinations (Clade 3.1+3.2—IncFII_{pHN7A8}, Clade 3.1+3.2—IncFII_{pHN7A8}:IncR, Clade 3.3—IncFII_{pHN7A8}:Inc_{pA1763-KPC}) led to the strong population expansion during 2007-2008 and subsequent maintenance of the prevalence and clonal dissemination of ST11/CG258 cpKP after 2008. They endowed cpKP with the phenotypes advantages in growth, competition and

655 resistance.

656

Supplementary Information

Three bacterium-plasmid golden combinations facilitate the spread of ST11/CG258 carbapenemase-producing *Klebsiella pneumoniae* in China

Cuidan Li^{1#}, Xiaoyuan Jiang^{1,2#}, Tingting Yang^{1#}, Yingjiao Ju^{1,3#}, Zhe Yin², Liya Yue¹,
Guanan Ma¹, Xuebing Wang¹, Ying Jing², Xinhua Luo², Shuangshuang Li^{1,3}, Xue
Yang^{1,3}, Fei Chen^{1,3,4,5*}, Dongsheng Zhou^{2*}

*To whom correspondence should be addressed. Tel: +86 010 66948503; E-mail: dongshengzhou1977@gmail.com

*Correspondence may also be addressed to Prof. Fei Chen. Tel: +86 010 84097460; Fax: +86 010 84097720; E-mail: chenfei@big.ac.cn

This PDF file includes:

Detailed methods

Table S2 to Table S7

Figure S1 to Figure S13

Table S1, presented as a separate document

[Table S2, included in this document](#)

[Table S3, included in this document](#)

[Table S4, included in this document](#)

[Table S5, included in this document](#)

[Table S6, included in this document](#)

[Table S7, included in this document](#)

[Figure S1, included in this document](#)

[Figure S2, included in this document](#)

[Figure S3, included in this document](#)

[Figure S4, included in this document](#)

[Figure S5, included in this document](#)

[Figure S6, included in this document](#)

[Figure S7, included in this document](#)

[Figure S8, included in this document](#)

[Figure S9, included in this document](#)

[Figure S10, included in this document](#)

[Figure S11, included in this document](#)

[Figure S12, included in this document](#)

[Figure S13, included in this document](#)

Table S2|Carbapenemase genes from our 420 cpKP isolates

Carbapenemase gene	Number of isolates (%)
<i>bla_{KPC}</i>	372 (88.57)
<i>bla_{KPC-2}</i>	369 (87.86)
<i>bla_{KPC-3}</i>	1 (0.24)
<i>bla_{KPC-5}</i>	2 (0.48)
<i>bla_{NDM}</i>	26 (6.19)
<i>bla_{NDM-1}</i>	25 (5.95)
<i>bla_{NDM-5}</i>	1 (0.24)
<i>bla_{IMP}</i>	19 (4.52)
<i>bla_{IMP-4}</i>	13 (3.10)
<i>bla_{IMP-38}</i>	6 (1.43)
<i>bla_{KPC}+bla_{NDM}</i>	3 (0.71)
<i>bla_{KPC-2}+bla_{NDM-1}</i>	3 (0.71)

Table S3|Carbapenemase genes from different STs/CGs of our 420 cpKp isolates

CG	ST	Number of isolates (%)				
		Total	<i>bla</i> KPC - carrying	<i>bla</i> NDM - carrying	<i>bla</i> KPC- and <i>bla</i> NDM - carrying	<i>bla</i> IMP - carrying
CG258	ST11	298	295 (99)		1 (0.3)	2 (0.7)
	ST2667	7	7 (100)			
	ST3348	6	6 (100)			
	ST258	2	1 (50.0)	1 (50.0)		
CG1	ST1	6	2 (33.3)	4 (66.7)		
CG12	ST12	1	1 (100)			
CG13	ST13	1	1 (100)			
CG15	ST15	17	16 (94.1)			1 (5.9)
	ST2237	6	6 (100)			
	ST3349	1		1 (100)		
	ST14	1				1 (100)
CG17	ST17	3		1 (33.3)		2 (66.7)
	ST16	1	1 (100)			
CG22	ST1010	1	1 (100)			
CG23	ST23	2	2 (100)			
	ST846	1				1 (100)
	ST218	1	1 (100)			
CG35	ST449	2			2 (100)	
CG37	ST37	4	2 (50.0)	1 (25.0)		1 (25.0)
	ST896	1	1 (100)			
CG40	ST40	1		1 (100)		
CG43	ST43	1				1 (100)
CG45	ST1493	1		1 (100)		
	ST1106	1	1 (100)			
CG65	ST65	2	2 (100)			
	ST685	1	1 (100)			
CG86	ST86	1	1 (100)			
CG147	ST147	7	2 (28.6)	5 (71.4)		
	ST273	4		4 (100)		
CG231	ST231	1	1 (100)			
CG292	ST3345	2				2 (100)
CG307	ST307	7	1 (14.3)			6 (85.7)
CG313	ST313	1		1 (100)		
CG395	ST395	1	1 (100)			
CG515	ST2176	1				1 (100)
CG661	ST661	1	1 (100)			

CG716	ST1958	5	5 (100)			
	ST3334	1	1 (100)			
CG815	ST268	5	5 (100)			
CG1306	ST1306	1		1 (100)		
CG2390	ST3350	1		1 (100)		
CG2670	ST2670	1		1 (100)		
CG3132	ST290	6	5 (83.3)	1 (16.7)		
CG1801	ST1333	1	1 (100)			
NA	ST2480	1		1 (100)		
NA	ST3333	1		1 (100)		
NA	ST1114	1				1 (100)
NA	ST2153	1	1 (100)			

Table S4|Inc groups of the 377 *bla*_{KPC}-carrying plasmids*

Inc group (n=32)	Number of plasmids (n=377)	%Percent
IncFII _{pHN7A8}	28	7.43
IncFII _{pHN7A8} :IncR	163	43.24
IncFII _{pHN7A8} :Inc _{pA1763} -KPC	59	15.65
IncFII _{pHN7A8} :IncN1	1	0.27
IncFII _{pHN7A8} :IncN1:IncR	2	0.53
IncFII _{pHN7A8} :Inc _{pA1763} -KPC:IncN1	2	0.53
IncFII _{pHN7A8} :IncFIB _{pFB2.3}	1	0.27
IncFII _{pKPHS2} :Inc _{pA1763} -KPC	36	9.55
IncFII _{pKPHS2} :IncR	5	1.33
IncFII _{pKPHS2} :IncFIB _{pSC138}	1	0.27
IncFII _{pKPHS2} :Inc _{pLT968725}	1	0.27
IncFII _{pKPHS2} :Inc _{pA1763} -KPC:IncR	2	0.53
IncFII _{p0716} -KPC:Inc _{pA1763} -KPC	30	7.96
IncFII _{p0716} -KPC:IncR	1	0.27
IncFII _{p0716} -KPC:IncFIB _{pSC138}	1	0.27
IncFII _{pCP020359} :Inc _{pA1763} -KPC	7	1.86
IncFII _{R100}	4	1.06
IncFII _{R100} :IncFIB _{plasmid F}	1	0.27
IncFII _{R100} :IncFIA _{pBK30661}	1	0.27
IncFII _{pBK30683}	1	0.27
IncX6	10	2.65
IncR	3	0.80
IncR:IncFIB _{plasmid F}	1	0.27
IncR:Inc _{pA1763} -KPC:IncN1	2	0.53
IncP-6	3	0.80
IncC	2	0.53
IncC:IncR	1	0.27
IncN1	1	0.27
IncFIA _{pBK30661}	2	0.53
Inc _{pA1763} -KPC	2	0.53
Inc _{pHS062105-3}	2	0.53
IncFIB _{pSC138}	1	0.27

* These 377 plasmids came from a total of 375 cpKP isolates. There were two different *bla*_{KPC}-carrying plasmids in each of the two following isolates: an IncFII_{pHN7A8}:IncR plasmid plus an IncX6 one in the G030 isolate, and an IncFII_{R100}:IncFIA_{pBK30661} plasmid plus an IncR:IncFIB_{plasmid F} one in the G300 isolate.

Table S5|The Inc group of blaKPC-carrying plasmids of the 38 complete ST11 KP genome downloaded from NCBI.

Inc group	Number	Percent (%)
IncFII _{pHN7A8}	3	7.5
IncFII _{pHN7A8} :IncN1	1	2.5
IncFII _{pHN7A8} :IncR	27	67.5
IncFII _{pHN7A8} :IncR:IncN1	1	2.5
IncFII _{pHN7A8} :Inc _{pA1763} -KPC	1	2.5
IncFII _{pHN7A8} :IncΔR	1	2.5
IncFII _K :IncR	2	5
IncFII _K :IncR:Inc _{pA1763} -KPC	1	2.5
IncR	3	7.5

Table S6| Percentage of cpKP isolates resistant to the 21 antibiotics in China*

Class	Antibiotics	Percentage (%)
Penicillins	Ampicillin	99.8538
	Ampicillin/sulbactam	0.956098
	Piperacillin	0.990834
	Piperacillin/tazobactam	0.925744
Cephalosporins, first generation	Cefazolin	0.991408
Cephalosporins, second generation	Cefuroxime	0.982398
	Cefotetan	0.93741
Cephalosporins, third generation	Ceftazidime	0.962959
	Ceftriaxone	0.945567
Cephalosporins, fourth generation	Cefepime	0.891937
Monobactams	Aztreonam	0.919133
Carbapenems	Imipenem	0.914203
	Meropenem	0.86514
Aminoglycosides	Amikacin	0.494484
	Gentamicin	0.647221
	Tobramycin	0.715353
Fluoroquinolones	Ciprofloxacin	0.782454
	Levofloxacin	0.681667
Furanes	Macrodantin	0.957
Sulfanilamides	Sulfamethoxazole/trimethoprim	0.702209

*Data are derived from all the 31 literatures published since 2017(1-31).

Table S7|PCR primers used in the competition experiment.

cpKP isolate*	ST/CG	<i>bla</i>_{KPC}-carrying plasmid	Target gene	Primer sequences
G134	ST11/CG258	IncFII _{pHN7A8}	G134_05212	F: 5'-ACCGAAACATTCTCCGCACT-3' R: 5'-CCTGCGGAAACAACCTGGTA-3'
G285	ST11/CG258	IncFII _{pHN7A8} :IncR	G285_01367	F: 5'-CGCTCTGAGAACGTCGTCAT-3' R: 5'-ACCTGGAAATGCGGGTCTTT-3'
G318	ST11/CG258	IncFII _{pHN7A8} :Inc _{pA1763} -KPC	G318_02254	F: 5'-CTCATCCATCGCACTACCCG-3' R: 5'-AGGGTAGGTGAAAAGCTCGC-3'
G165	ST11/CG258	IncFII _{p0716} -KPC:Inc _{pA1763} -KPC	G165_02217	F: 5'-TTACAAGGGCCGCTGACATT-3' R: 5'-CGGGTAGTGCGATGGATGAG-3'
G344 (control)	Non-CG258	IncFII _{pKPHS2} :Inc _{pA1763} -KPC	G344_00764	F: 5'-TTGCCTTTCAGATCGCGACT-3' R: 5'-GTCTCAGGGCCATCAGTAGC-3'

*Each isolate contained a single plasmid.

Figure S1. An population snapshot of the 5,099 global KP isolates. These isolates included our 420 cpKp isolates and the 4,679 isolates from the *Klebsiella* MLST database. The lines between STs indicated single-locus variants. The size of circle represented number of isolates. The circles with green rings represented the eight novel STs found in our 420 cpKp isolates, while those with cyan rings stood for the STs found in both our 420 cpKp isolates and the MLST database.

Figure S2. A maximum-likelihood clustering tree of the 2,300 global KP isolates. These isolates included our 420 cpKp isolates and the 1,880 isolates with determined genome sequences from GenBank (last accessed April 10, 2018). The tree was constructed from the 610,814 core SNPs of these 2,300 genome sequences. *K. variicola* DSM 15968 was used as the outgroup but not shown in the tree.

Figure S3. Prevalence of carbapenemase genes in CG258 and non-CG258 cpKP isolates. The numbers on the y-axis represented the percentage values. The *p* values were obtained using Fisher exact test. ***, statistically significant with *p* < 0.0001.

Figure S4. Alignment of the 28 *bla_{KPC}*-carrying IncFII_{pHN7A8} plasmids from our 420 cpKp isolates. The color rings represented the fully sequenced plasmids, while the grey rings stood for those with draft sequences.

Figure S5 Alignment of the 163 blaKPC-carrying IncFIIpHN7A8:IncR plasmids from our 420 cpKp isolates. The color rings represented the fully sequenced plasmids, while the grey rings stood for those with draft sequences.

Figure S6. Alignment of the 59 *bla*_{KPC}-carrying IncFII_{pHN7A8}:Inc_{PA1763}-KPC plasmids from our 420 cpKp isolates. The color rings represented the fully sequenced plasmids, while the grey rings stood for those with draft sequences.

Figure S7. Alignment of the 30 blaKPC-carrying IncFII0716-KPC:IncA1763-KPC plasmids from our 420 cpKp isolates. The color rings represented the fully sequenced plasmids, while the grey rings stood for those with draft sequences.

Figure S8. Alignment of the 36 *bla*_{KPC}-carrying IncFII_{pKPHS2}:Inc_{PA1763}-KPC plasmids from our 420 cpKp isolates. The color rings represented the fully sequenced plasmids, while the grey rings stood for those with draft sequences.

Figure S9. Divergence of IncFII replicons and their prevalence in CG258 and non-CG258. **a**, A maximum likelihood tree of seven subsets of IncFII replicons. The IncFIA replicon of plasmid F (accession number AP001918) was used the outgroup. **b**, The prevalence of *bla*_{KPC}-carrying plasmids with IncFII replicons in CG258 and non-CG258 cpKP isolates.

Figure S10. Local *bla*_{KPC} genetic environments. Genes were denoted by arrows. Genes, mobile genetic elements and other features were colored based on the functional classification. Shadow denoted homology regions ($\geq 95\%$ identity).

Figure S11. Antimicrobial susceptibility data of cpKP isolates. Shown were the drug resistance profile of our 420 cpKP isolates (a), and the resistance rates [resistant/(sensitivity + resistant)] of CG258 and non-CG258 isolates for each indicated antibiotics. A total of 21 antibiotics in nine classes were tested. The *p* values were obtained using Fisher's exact test. NS, no significant difference. ** and ***, statistically significant with *p* < 0.001 and *p* < 0.0001, respectively.

Figure S12. Boxplots showing the numbers of classes of antibiotics that CG258 and non-CG258 isolates were resistant to. The p value was tested using Wilcoxon test. *, statistically significant with $p < 0.0001$.**

Figure S13. Carbapenem sales/consumption in China. a, Carbapenem sales in China from 2005 to 2009. **b,** Meropenem consumption in China from 2007 to 2011.

References

1. Lin D, Chen J, Yang Y, Cheng J, & Sun C (2018) Epidemiological Study of Carbapenem-resistant Klebsiella Pneumoniae. *Open Med (Wars)* 13:460-466.
2. Lin L, Xiao X, Wang X, Xia M, & Liu S (2020) In Vitro Antimicrobial Susceptibility Differences Between Carbapenem-Resistant KPC-2-Producing and NDM-1-Producing Klebsiella pneumoniae in a Teaching Hospital in Northeast China. *Microb Drug Resist* 26(2):94-99.
3. Liu L, *et al.* (2018) Carbapenem-resistant Isolates of the Klebsiella pneumoniae Complex in Western China: The Common ST11 and the Surprising Hospital-specific Types. *Clin Infect Dis* 67(suppl_2):S263-S265.
4. Meng X, *et al.* (2019) Assessing Molecular Epidemiology of Carbapenem-resistant Klebsiella pneumoniae (CR-KP) with MLST and MALDI-TOF in Central China. *Sci Rep* 9(1):2271.
5. Ou Q, Li W, Li B, & Yu C (2017) Prevalence of Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) and the Distribution of Class 1 Integron in Their Strains Isolated from a Hospital in Central China. *Chin Med Sci J* 32(2):107-102.
6. Shi Y, *et al.* (2020) Characterization and genome sequencing of a novel T7-like lytic phage, kpsk3, infecting carbapenem-resistant Klebsiella pneumoniae. *Arch Virol* 165(1):97-104.
7. Shu LB, *et al.* (2019) Prevalence and phenotypic characterization of carbapenem-resistant Klebsiella pneumoniae strains recovered from sputum and fecal samples of ICU patients in Zhejiang Province, China. *Infect Drug Resist* 12:11-18.
8. Wang Q, *et al.* (2018) Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016). *Clin Infect Dis* 67(suppl_2):S196-S205.
9. Chen Z & Xiang J (2018) [Preliminary study on resistance mechanism and virulence features in carbapenems-resistant Klebsiella pneumoniae from burn patients]. *Zhonghua Shao Shang Za Zhi* 34(11):796-801.
10. Chiu SK, *et al.* (2017) Tigecycline resistance among carbapenem-resistant Klebsiella Pneumoniae: Clinical characteristics and expression levels of efflux pump genes. *PLoS One* 12(4):e0175140.
11. Dong F, *et al.* (2018) Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Chinese Children's Hospital: Predominance of New Delhi Metallo-beta-Lactamase-1. *Microb Drug Resist* 24(2):154-160.
12. Li J, *et al.* (2019) Isolation and characterization of a sequence type 25 carbapenem-resistant hypervirulent Klebsiella pneumoniae from the mid-south region of China. *BMC Microbiol* 19(1):219.
13. Liao Y, *et al.* (2017) Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae. *Exp Ther Med* 13(3):1003-1010.
14. Sun WM, *et al.* (2019) [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant Klebsiella pneumoniae bloodstream infections]. *Zhonghua Nei Ke Za Zhi* 58(8):566-571.
15. Tang X, Xiao M, Zhuo C, Xu Y, & Zhong N (2018) Multi-level analysis of bacteria isolated from inpatients in respiratory departments in China. *J Thorac Dis* 10(5):2666-2675.
16. Tian D, Pan F, Wang C, Sun Y, & Zhang H (2018) Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae among pediatric patients in

- Shanghai. *Infect Drug Resist* 11:1935-1943.
17. Tseng SP, *et al.* (2017) The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant *Klebsiella pneumoniae* isolates in Taiwan. *J Microbiol Immunol Infect* 50(5):653-661.
18. Wang Z, *et al.* (2019) Outbreak of blaNDM-5-Harboring *Klebsiella pneumoniae* ST290 in a Tertiary Hospital in China. *Microb Drug Resist* 25(10):1443-1448.
19. Yan J, *et al.* (2017) Multidrug Resistance Mechanisms of Carbapenem Resistant *Klebsiella pneumoniae* Strains Isolated in Chongqing, China. *Ann Lab Med* 37(5):398-407.
20. Yan Z, *et al.* (2019) Prospective investigation of carbapenem-resistant *Klebsiella pneumoniae* transmission among the staff, environment and patients in five major intensive care units, Beijing. *J Hosp Infect* 101(2):150-157.
21. Yu F, *et al.* (2019) Dissemination of *Klebsiella pneumoniae* ST11 isolates with carbapenem resistance in integrated and emergency intensive care units in a Chinese tertiary hospital. *J Med Microbiol* 68(6):882-889.
22. Yu L, *et al.* (2019) Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant *Klebsiella pneumoniae* in vitro. *Front Cell Infect Microbiol* 9:422.
23. Zeng L, *et al.* (2019) Prevalence of Carbapenem-Resistant *Klebsiella pneumoniae* Infection in Southern China: Clinical Characteristics, Antimicrobial Resistance, Virulence, and Geographic Distribution. *Microb Drug Resist*.
24. Zhan L, *et al.* (2017) Outbreak by Hypermucoviscous *Klebsiella pneumoniae* ST11 Isolates with Carbapenem Resistance in a Tertiary Hospital in China. *Front Cell Infect Microbiol* 7:182.
25. Zhang J, *et al.* (2019) Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant *Klebsiella pneumoniae* in vitro. *Ann Palliat Med* 8(5):622-631.
26. Zhang P, *et al.* (2020) Emergence of ceftazidime/avibactam resistance in carbapenem-resistant *Klebsiella pneumoniae* in China. *Clin Microbiol Infect* 26(1):124 e121-124 e124.
27. Zhang X, Chen D, Xu G, Huang W, & Wang X (2018) Molecular epidemiology and drug resistant mechanism in carbapenem-resistant *Klebsiella pneumoniae* isolated from pediatric patients in Shanghai, China. *PLoS One* 13(3):e0194000.
28. Zhang Y, *et al.* (2018) Risk factors for carbapenem-resistant *K. pneumoniae* bloodstream infection and predictors of mortality in Chinese paediatric patients. *BMC Infect Dis* 18(1):248.
29. Zhao D, Zuo Y, Wang Z, & Li J (2019) Characterize carbapenem-resistant *Klebsiella pneumoniae* isolates for nosocomial pneumonia and their Gram-negative bacteria neighbors in the respiratory tract. *Mol Biol Rep* 46(1):609-616.
30. Zheng B, *et al.* (2017) Molecular Epidemiology and Risk Factors of Carbapenem-Resistant *Klebsiella pneumoniae* Infections in Eastern China. *Front Microbiol* 8:1061.
31. Gu B, *et al.* (2019) Clonal dissemination of KPC-2-producing *Klebsiella pneumoniae* ST11 and ST48 clone among multiple departments in a tertiary teaching hospital in Jiangsu Province, China. *Ann Transl Med* 7(23):716.